Cytometry and Analytical Methods in COVID‐19 Diagnostics and Potential Treatment: A Special Issue on Cytometry Part A
Le Zhang,Dong-Yan Jin
DOI: https://doi.org/10.1002/cyto.a.24719
IF: 4.714
2023-01-01
Cytometry Part A
Abstract:COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, poses significant challenges for healthcare systems and medical institutions worldwide. Several countries including the USA announced in recent weeks the end of the Coronavirus pandemic. This seemed to be a timely sign as expectations of the last years projecting that the pandemic would be over in not later than 2023. Unfortunately, this was wishful thinking and the WHO still classifies the COVID-19 disease as a pandemic. So, The COVID-19 pandemic in 2023: far from over as reemphasized in a recent editorial of The Lancet.1 In the last few decades, flow cytometry has redefined the field of biology. More encouragingly, it recently gave birth to flow virometry, a new way to detect, analyze, and characterize single viral particles. Throughout this pandemic, advances in this field are not only catalyzing our understanding of COVID-19 infections and ways to diagnostics but also accelerating the development of new potential therapies and identifications of potential targets for new vaccines. We are excited to announce this Cytometry Part A special issue “Cytometry and analytical methods in COVID-19 diagnostics and potential treatment,” bringing together several research articles and reviews on exploring the use of flow cytometry techniques towards clinical opportunities in the detection and diagnostics of COVID-19. This collection of thought-provoking articles highlights the amazing transformation witnessed by the COVID-19 pandemic and the problem-driven research using flow cytometry as well as the perspectives on the opportunities, technical and conceptual challenges ahead. Topics include studies using high-throughput flow cytometry to dissect clinical heterogeneity in COVID-19, impacts of age and gender on lymphocytes which are reduced in COVID-19 patients, roles of the number of circulating CD26 expressing cells in critical COVID-19 illness, and many more. This special issue describes several applications of biomarkers analyzed by flow cytometry in COVID-19 patients, highlighting the diversities of this emerging field of research. This interplay is nicely captured in two research articles that present the significant progress achieved in the last 2 years. Phillip Löhr et al. report (This issue, include pp. 127-135) that cell counts of total lymphocytes, B, NK, cytotoxic and helper T cells are reduced in patients with severe COVID-19 and this tendency was observed in patients with moderate COVID-19. However, in multivariate analysis, there is an age-dependent reduction of the total central memory (CM), early CD8+ cell subsets, and naïve, CM, and regulatory CD4+ cell subsets. In addition to age, male gender significantly influenced lower counts of CD3+ and CD4+ lymphocyte numbers. This implies that age and gender must be considered in COVID-19 diagnosis when interpreting the altered cell counts. Another study by Joanne T. deKay et al. (This issue, include pp. 153-161) evaluated the number of CD26-expressing cells in the peripheral blood of patients with COVID-19 within 72 hours of admission. Significantly, a low number of CD26-expressing cells was associated with critical severity COVID-19 disease. Still, conversely, increasing numbers of CD26-expressing cells over the first week of standard treatment was associated with good outcomes that indicate the number of circulating CD26 cells might be a marker of recovery or the therapeutic efficacy of anti-COVID-19 treatment. Besides, two methodologies have been included in this special issue. Julian J. Freen-van Heeren (This issue, include pp. 107-109) introduced a SARS-CoV-2 Flow-FISH assay using single-molecule FISH probes to investigate a potentially druggable host process. The potential advantages of Flow-FISH, including high-throughput benefits and the option for a higher degree of multiplexing, highlight this approach. Yuqi Zhou et al. (This issue, include pp. 162-167) studied the long-term effects of Pfizer-BioNTech COVID-19 vaccinations on platelets by using the image-based single-cell profiling of circulating platelet aggregates in the blood of healthy human subjects before and after they received multiple Pfizer-BioNTech (BNT162b2) vaccine doses over a period of nearly 1 year. They found no significant or persisting platelet aggregation trends following the vaccine doses, indicating that any effects of vaccinations on platelet turnover, platelet activation, platelet aggregation, and platelet-leukocyte interaction were insignificant. Moving to another topic area, the angiotensin-converting enzyme-2 (ACE2) has been recognized as the entry receptor for the SARS-CoV-2 infecting host cells, which may act as a limiting factor for a viral infection at the initial stage. Using flow cytometry, Xiang Song et al. (This issue, include pp. 136-145) demonstrated that there was little to no expression of ACE2 on most of the human peripheral blood-derived immune cells, including CD4+ T, CD8+ T, activated CD4+/CD8+ T, Tregs, Th17, NKT, B, NK cells, as well as on platelets or the surface of human primary pulmonary alveolar epithelial cells. However, The ACE2 expression was markedly upregulated on the activated type 1 macrophage (M1), which highlights the importance of macrophages in the pathogenesis and treatment of COVID-19 (This issue, include pp. 146-152). A review article by Irene del Molino del Barrio et al. (This issue, include pp. 117-126) summarizes the application of high-throughput flow cytometry in detecting clinical heterogeneity in COVID-19 patients or patients with cancer and discusses several possibilities for overcoming the current limitation of flow cytometry and for further developing methodology. For example, they introduced a high-throughput flow cytometry platform (COVID-IP) that featured eight distinct flow cytometry panels collectively covering detailed analyses of lymphocytes and can be integrated with other analytical approaches, including the measurements of SARS-CoV-2-specific serum antibody titters, plasma cytokine/chemokine levels, and in-depth clinical annotation. Besides, they report how selective differences between T cell subsets were revealed by a newly described flow cytometric TDS assay to distinguish actively cycling T cells in the peripheral blood. It has been over half of a century since the first fluorescence-based flow cytometry was developed in 1968. In recent decades, flow cytometry has been used for virus studies. Flow cytometry plays a crucial role in COVID-19 diagnostics and potential treatment during this pandemic. This special issue is an exposé of developments and achievements that continue to propel us on this exciting journey of discovery in virus detection using flow cytometry. We hope you enjoy reading these papers.